Clinical Trials Browser

Phase 2/3 × Breast × Clear all

NCT02364557 2026-05-19

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

Phase 2/3 Completed

129 enrolled 23 charts

Breast Neoplasms, Lymphatic Metastasis

NCT05889390 2026-05-15

NeoHTerMa

Phase 2/3 Active not recruiting

Hyperthermia, Breast Neoplasms

NCT07413939 2026-05-11

BREnnA

Phase 2/3 Recruiting

HER2-positive Breast Cancer

NCT06926868 2026-04-30

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06062810 2026-04-23

Drugs-SNPs

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT07544056 2026-04-22

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 2/3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT04715958 2026-04-06

SHAPE Neoadjuvant Chemotherapy Response

Phase 2/3 Recruiting

Anatomic Stage III Breast Cancer AJCC v8

NCT03315364 2026-04-01

OPTIMAL

Phase 2/3 Active not recruiting

Breast Neoplasms, Recurrence

NCT07294508 2026-03-20

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Phase 2/3 Recruiting

Breast Neoplasms

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

NCT05766891 2026-03-16

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery

Phase 2/3 Recruiting

Breast Neoplasms

NCT03077841 2026-03-05

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Phase 2/3 Suspended

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT07410169 2026-02-13

Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT06009627 2026-02-10

Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Phase 2/3 Completed

Breast Neoplasms

NCT07373782 2026-01-28

Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer

Phase 2/3 Recruiting

Microcephaly, Primary Autosomal Recessive, 6, Breast Neoplasms

NCT07366840 2026-01-26

BRIGHT

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT05860465 2026-01-14

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Phase 2/3 Recruiting

Breast Neoplasms

NCT04290793 2026-01-07

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT07310758 2025-12-30

Contrast-enhanced Ultrasound for Sentinel Node Detection

Phase 2/3 Recruiting

BreastDermatologicHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Melanoma

NCT07294534 2025-12-19

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT06891833 2025-10-02

A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Phase 2/3 Recruiting

HER2-positive Breast Cancer

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Phase 2/3 Completed

130 enrolled 8 charts

Breast Carcinoma In Situ, Breast Neoplasms

NCT05744687 2025-08-17

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Phase 2/3 Recruiting

Breast Neoplasms

NCT06958627 2025-05-06

any

Phase 2/3 Recruiting

HER2 Positive Breast Cancer

NCT05288777 2025-04-18

Breast53

Phase 2/3 Recruiting

Breast Neoplasms

NCT05555706 2025-04-15

Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Phase 2/3 Completed

Triple Negative Breast Neoplasms

NCT01779206 2025-04-08

ADAPT

Phase 2/3 Completed

Breast Neoplasms

NCT06910072 2025-04-04

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer

Phase 2/3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT01781338 2025-02-27

ADAPT

Phase 2/3 Completed

Breast Neoplasms

NCT06769919 2025-01-10

A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT05747794 2024-12-17

AIPAC-003

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT02883361 2024-12-05

MI for AIs

Phase 2/3 Withdrawn

Breast Neoplasms, Medication Adherence

NCT00221221 2024-11-05

Physical Activity Promotion in Breast Cancer Survivors

Phase 2/3 Completed

Breast Neoplasms, Motor Activity

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Phase 2/3 Active not recruiting

HER2-positive Breast Cancer

NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Phase 2/3 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03500380 2024-02-20

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Phase 2/3 Unknown

Breast Diseases, Breast Neoplasms

NCT06268327 2024-02-20

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Phase 2/3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05189535 2024-01-23

"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"

Phase 2/3 Completed

Breast Neoplasms, Peripheral Nervous System Diseases

NCT05523609 2023-12-01

Vitamin D and Calcium Supplementation in Breast Cancer

Phase 2/3 Unknown

Breast Neoplasms

NCT02068092 2023-10-10

Olive Oil for High Risk Breast Cancer Prevention in Women

Phase 2/3 Completed

51 enrolled 6 charts

Breast Neoplasms

NCT02221999 2023-08-29

SHPD002

Phase 2/3 Active not recruiting

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT05727098 2023-06-08

Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy.

Phase 2/3 Completed

Breast Neoplasms

NCT03564171 2023-04-12

Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer

Phase 2/3 Completed

Breast Neoplasms

NCT05804916 2023-04-07

Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer

Phase 2/3 Recruiting

Breast Neoplasms

NCT05802342 2023-04-06

A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer

Phase 2/3 Unknown

To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients

NCT04924699 2023-03-17

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 2/3 Unknown

Breast Neoplasms

NCT03354611 2023-03-16

Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging

Phase 2/3 Terminated

Breast Neoplasms

NCT04803539 2023-02-21

Artemis

Phase 2/3 Recruiting

Breast Neoplasms

NCT04554056 2022-12-02

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Phase 2/3 Completed

Breast Cancer Female